USPTO serial 87982200
GEOMX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 24, 2019
- Examiner
- MILLER, JUSTIN T
- Law office
- Historical data usage
What this means
Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.
Need help with GEOMX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Seattle, WA, US
Seattle, WA, US
BILLERICA, MA, US
Seattle, WA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alyssa Worsham
Alyssa Worsham WILSON SONSINI GOODRICH & ROSATI650 PAGE MILL ROADPALO ALTO, CA 94304-1050United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | reagents and instruments for scientific, research or non-medical or veterinary diagnostic use in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; diagnostic reagents for scientific or research use in the fields of cancer, neurology and infectious disease; reagents for scientific, research or non-medical or veterinary diagnostic use relating to molecular identification and digital quantification; reagents for scientific, research or non-medical or veterinary diagnostic use containing antibodies and nucleic acids; reagent kits comprising primarily reagents for scientific, research or non-medical or veterinary diagnostic use in the fields of cancer, neurology and infectious disease; reagents for immuno-histochemistry detection and in situ-hybridization detection for scientific, research or non-medical or veterinary diagnostic use; test kits for scientific, research or non-medical or veterinary diagnostic use comprising reagents, slides, solid matrix materials, microfluidic devices and support documentation, namely, instructional manuals, therefor; test kits comprising reagents for scientific, research or non-medical or veterinary diagnostic use relating to molecular identification and digital quantification; reagents for in vitro use in clinical chemistry and molecular biology; reagents for clinical or medical laboratory use, namely, reagents for pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling, nucleic acid sequencing, and clinical, oncology, neurology, and infectious disease diagnostics; multiparameter quantitative detection and analysis products and technology for research and diagnostics for a variety of uses in the health care and other life science sectors, namely, reagents for scientific or medical research use, diagnostic preparations and reagents for scientific or research uses, namely, pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; test kits, consisting of chemical preparations for scientific purposes, in particular for the detection, diagnosis, progress monitoring and progress prediction of diseases, including inflammations, infections, disorders of the central nervous systems, cardiovascular, neurological, endocrine, autoimmune and genetic disorders and cancers | ACTIVE | Sep 3, 2019 |
| 009 | automated apparatus in the nature of automated laboratory equipment and computer systems comprised of computer hardware and software for detection and analysis of biomolecules for scientific use; automated apparatus in the nature of automated laboratory equipment and computer systems comprised of computer hardware and software for scientific research, namely, for detecting, collecting and processing optical signals and images, into data for use in the analysis of biomolecules in connection with scientific or medical research; automated apparatus in the nature of automated laboratory equipment in the nature of digital imagers, digital displays, microscopes, robotics, fluidic stations and computer systems for staining and/or visualization of tissue or cell based samples for diagnostic or scientific use; automated apparatus in the nature of automated laboratory equipment in the nature of digital imagers, digital displays, microscopes, robotics and computer systems for digitizing images of biological tissue for use in connection with pathology; automated apparatus in the nature of automated laboratory equipment in the nature of digital imagers, digital displays, microscopes, robotics and computer systems for capturing digital images of microscope slides of biological tissue, storage of digitized microscope slide images in a data storage area, and display of digitized microscope slide images; automated apparatus in the nature of automated laboratory equipment in the nature of digital imagers, digital displays, microscopes, robotics, fluidic stations and computer systems comprised of computer hardware and software for detection and analysis of, pathology, gene expression, RNA transcription, RNA translation and nucleic acid sequencing; computer hardware and software to enable pathologists to diagnose disease; computer hardware and software for the electronic scanning of clinical pathology slides; computer hardware and software for pathologists to render and report diagnoses and results of scientific research; computer hardware and software for scientific or research uses, namely, pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription and microRNA expression profiling and nucleic acid sequencing; computer hardware and software for digitizing, processing and storing images of biological tissues and cells; computer hardware and software for analyzing the results of tissues and cell based samples obtained through operation of tissue and cell sample staining and visualization apparatus; computer hardware and software for identifying and diagnosing cancer and other diseases and processing digital images; computer hardware and software for viewing, analyzing, managing, reporting, and archiving digital images; laboratory equipment for sample preparation, mixing, hybridization, incubation, washing, location and imaging, namely, robotic equipment, fluid mixers, pumps, valves, and containers, reagent holders, sample containers and microfluidic devices, optical devices, scanning microscopes, fluorescent microscopes, digital micromirror devices, electromagnetic sensors and replacement parts therefor in the fields of scientific research; computer systems, namely, software and data files to acquire, analyze, manage and report biological information | ACTIVE | Sep 3, 2019 |
| 010 | clinical and medical diagnostic instruments, namely, histopathology instruments and nucleic acid sequencers; clinical and medical diagnostic instruments for analysis of tissue and/or cell based samples, all for medical purposes; clinical and medical diagnostic instruments for performing immunohistochemistry and in situ-hybridization staining reactions, histological and pathological staining and image processing and analysis; histopathology instruments for clinical purposes; clinical and medical diagnostic instruments for immunohistochemistry and in situ-hybridization analyses; clinical and medical diagnostic instruments for the electronic scanning of clinical pathology slides, processing and storing images of biological tissues and cells and digitizing, processing and storing images of biological tissues and cells | ACTIVE | Sep 3, 2019 |
| 042 | research and product development services for others in the field of biotechnology; medical and scientific research services for others in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; medical and scientific research in the field of cancer treatment and diagnosis; medical and scientific research services for others in the field of infectious disease; medical and scientific research services for others in the field of neurology; medical and scientific research services for others, namely, research and design in the field of testing, analyzing and examining biological samples, medical samples, and cell samples; providing laboratory research services for others in the field of gene expression and genetic data mining; research and development services for others for acquiring, analyzing, and managing biological and genetic information in the fields of diagnostic reagents, forensics, medicine, genetics, and environment; research, design, and development services for others in the fields of diagnostic reagents, compounds and devices, measuring apparatus for use in product research and development, separation and purification processes | ACTIVE | Apr 1, 2019 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NanoString Technologies, Inc.
- Other trademarks owned by NanoString Technologies, Inc.
- Other trademarks owned by BRUKER SPATIAL BIOLOGY, INC.
- Other trademarks owned by NanoString Technologies, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named GEOMX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 17, 2026 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Mar 17, 2026 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Mar 16, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Dec 11, 2025 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Dec 24, 2024 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jul 4, 2024 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Dec 24, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 21, 2019 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Nov 20, 2019 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Oct 28, 2019 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Oct 28, 2019 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Oct 25, 2019 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Oct 23, 2019 | IUAF | USE AMENDMENT FILED | — |
| Oct 23, 2019 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Oct 23, 2019 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Oct 23, 2019 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Oct 3, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 2, 2019 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 2, 2019 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Aug 15, 2019 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Aug 15, 2019 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| Aug 15, 2019 | PETG | PETITION TO REVIVE-GRANTED | — |
| Aug 15, 2019 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Aug 5, 2019 | EXT1 | SOU EXTENSION 1 FILED | — |
| Feb 5, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 11, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 11, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 21, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 2, 2018 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Nov 2, 2018 | ALIE | ASSIGNED TO LIE | — |
| Oct 18, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 15, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 14, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 14, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 31, 2018 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Aug 31, 2018 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Aug 31, 2018 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Aug 30, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| May 18, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 12, 2018 | NWAP | NEW APPLICATION ENTERED | — |